Saturday, February 27, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

DARPA Seeks Innovations in Rapid DNA Molecule Manufacturing

by Global Biodefense Staff
April 10, 2020
Biodefense Industry News

DARPA is interested in understanding the feasibility of rapid, flexible manufacturing of DNA molecules for synthetic biology and therapeutic applications.

Small business interests are invited to submit innovated concepts under a new funding opportunity from the Defense Advanced Research Projects Agency (DARPA).

There is a critical DoD need to be able to rapidly and efficiently synthesize highly accurate kilobase (kb) pair length DNA constructs for medical countermeasure and synthetic biology applications.

Several DARPA programs and technologies (e.g., Living Foundries, PRemptive Expression of Protective Alleles and Response Elements (PREPARE), and Pandemic Prevention Platform (P3) rely heavily on synthetic DNA and the timely generation, manipulation, and delivery of genetic constructs. Current synthetic DNA production is costly, time-consuming, and requires highly specialized technical expertise and equipment. Consequently, few commercial suppliers are capable of producing synthetic DNA at a length that is appropriate for DARPA technologies (i.e., >2,500 base pairs) in the days-long turnaround time required for rapid response.

First, due to the limited capability base, commercial sources experience significant backlog in synthetic DNA production services, extending research and development timelines dependent on gene-encoded products, and increasing costs for the consumer. Second, current methods for synthesis or assembly of kilobase length constructs are often error prone, requiring manual purification and/or analytics steps to achieve the final product. Third, as demand for synthetic DNA production increases, any achieved throughput increases will need to maintain or even decrease the cost per base pair.

To achieve these goals, DARPA seeks methods capable of rapidly generating a panel of

synthetic DNA meeting the following objectives:

  • Each product sequence must be greater than 2,500 base pairs
  • Demonstrate a platform error rate of less than 1 per 5000 base pairs
  • Synthesis of at least 200 unique sequences (Phase I) in under one week
  • Synthesis of at least 500 unique sequences (Phase II) in under one week
  • Technology and commercial model with a cost per base pair to the consumer comparable to current vendors

For this opportunity, DARPA will accept Phase I proposals for costs of up to $225,000 for a 12-month period of performance. If a proposer can provide adequate documentation to substantiate that the scientific and technical requirements have been met, Direct to Phase II (DP2) authority may be exercised for proposals up to for costs of up to $1,750,000 (for a 24-month base period).

The objective of Phase I is to develop rapid DNA synthesis methods capable of generating DNA molecules greater than 2,500 base pairs in length. The synthesis method should be capable of producing 200 unique DNA sequences in less than one week in quantities sufficient for downstream cloning into expression vectors. Within the one-week production timeframe, the synthesized DNA molecules will need to be purified and analyzed for sequence identity relative to the input sequence and any residual impurities. At the end of Phase I, performers will need to demonstrate feasibility for producing 200 unique DNA sequences based on DARPA-defined targets in less than one week.

Phase II aims to demonstrate a flexible, multiplexed platform for the rapid synthesis of DNA molecules based on the basic prototype developed during Phase I. The platform should enable scaled synthesis of at least 500 unique gene sequences but preferably 1,000 unique sequences. Additionally, the platform at scale should generate products at a cost of <$0.01 per base pair. At the end of Phase II, performers will demonstrate the feasibility of producing 500-1000 unique DNA sequences based on DARPA-defined targets in less than one week.

Additional details are available at the federal contracting website under Notice ID: HR001120S0019-02. The response deadline is Apr 20, 2020 05:00 pm EDT.

Tags: DARPARequest for Proposals

Related Posts

Self-Decontaminating PPE Fabric
CBRNE

DRIVE ReDIRECT: Program Seeks to Develop Countermeasures Against Chemical Threats

October 31, 2020
Emerging Infections Network – Managing Travelers Who Acquire Disease Abroad
Biosurveillance

Emerging Infections Network – Managing Travelers Who Acquire Disease Abroad

October 27, 2020
State Department: Reducing Revisionist State Biological and Chemical Weapons Threats
CBRNE

State Department: Reducing Revisionist State Biological and Chemical Weapons Threats

October 27, 2020
Securing Synthetic Biology Data At Risk During the COVID-19 Pandemic
Biosecurity

Securing Synthetic Biology Data At Risk During the COVID-19 Pandemic

October 13, 2020
Load More

Latest News

First Human Trial of COVID-19 Vaccine Finds it is Safe and Induces Rapid Immune Response

COVID-19 Vaccination: What We Can Learn From the Great Polio Vaccine Heist of 1959

February 24, 2021
Sign on street in Conakry that says Ebola in large letters

Why Ebola is Back in Guinea and Why the Response Must Be Different This Time

February 24, 2021
How Roald Dahl Became a Passionate Vaccine Advocate

How Roald Dahl Became a Passionate Vaccine Advocate

February 23, 2021
How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

February 23, 2021

Upcoming Events

Mar 1
Virtual Event
All day

Rare Disease Day at NIH 2021 – Virtual Conference

Mar 2
Virtual Event
March 2 - March 5

Effectiveness of Non-Vaccine Influenza Control Measures

Mar 2
Virtual Event
4:00 pm - 6:00 pm

RNA Viruses: How They Do What They Do

Mar 2
Virtual Event
5:00 pm - 7:00 pm

COVID Seminar Series – Hindsight is 2020

Mar 4
Virtual Event
10:00 am - 1:30 pm

Vulnerabilities in U.S. Chemical Weapons Detection, Identification, and Tracing

View More
Tweets by GlobalBioD

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe

© 2021 Stemar Media Group LLC